Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1980 1
1984 1
1985 3
1986 1
1987 1
1988 1
1989 2
1990 4
1991 5
1992 2
1993 6
1994 2
1995 2
1996 4
1997 2
1998 5
1999 4
2000 3
2001 6
2002 5
2003 1
2004 3
2005 6
2006 8
2007 12
2008 19
2009 21
2010 25
2011 27
2012 35
2013 33
2014 27
2015 40
2016 79
2017 61
2018 68
2019 59
2020 88
2021 121
2022 155
2023 143
2024 76

Text availability

Article attribute

Article type

Publication date

Search Results

1,049 results

Results by year

Filters applied: . Clear all
Page 1
Ferroptosis and ferritinophagy in diabetes complications.
He J, Li Z, Xia P, Shi A, FuChen X, Zhang J, Yu P. He J, et al. Among authors: shi a. Mol Metab. 2022 Jun;60:101470. doi: 10.1016/j.molmet.2022.101470. Epub 2022 Mar 15. Mol Metab. 2022. PMID: 35304332 Free PMC article. Review.
AMPK: The key to ischemia-reperfusion injury.
Cai J, Chen X, Liu X, Li Z, Shi A, Tang X, Xia P, Zhang J, Yu P. Cai J, et al. Among authors: shi a. J Cell Physiol. 2022 Nov;237(11):4079-4096. doi: 10.1002/jcp.30875. Epub 2022 Sep 22. J Cell Physiol. 2022. PMID: 36134582 Review.
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Huang J, Liu D, Wang Y, Liu L, Li J, Yuan J, Jiang Z, Jiang Z, Hsiao WW, Liu H, Khan I, Xie Y, Wu J, Xie Y, Zhang Y, Fu Y, Liao J, Wang W, Lai H, Shi A, Cai J, Luo L, Li R, Yao X, Fan X, Wu Q, Liu Z, Yan P, Lu J, Yang M, Wang L, Cao Y, Wei H, Leung EL. Huang J, et al. Among authors: shi a. Gut. 2022 Apr;71(4):734-745. doi: 10.1136/gutjnl-2020-321031. Epub 2021 May 18. Gut. 2022. PMID: 34006584 Free PMC article.
Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
Shi AP, Tang XY, Xiong YL, Zheng KF, Liu YJ, Shi XG, Lv Y, Jiang T, Ma N, Zhao JB. Shi AP, et al. Front Immunol. 2022 Jan 17;12:785091. doi: 10.3389/fimmu.2021.785091. eCollection 2021. Front Immunol. 2022. PMID: 35111155 Free PMC article. Review.
ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression.
Zhang W, Zhong W, Wang B, Yang J, Yang J, Yu Z, Qin Z, Shi A, Xu W, Zheng C, Schuchter LM, Karakousis GC, Mitchell TC, Amaravadi R, Herlyn M, Dong H, Gimotty PA, Daaboul G, Xu X, Guo W. Zhang W, et al. Among authors: shi a. Dev Cell. 2022 Feb 7;57(3):329-343.e7. doi: 10.1016/j.devcel.2022.01.002. Epub 2022 Jan 31. Dev Cell. 2022. PMID: 35085484 Free PMC article.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Among authors: shi a. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
1,049 results